
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 4.530 | 4.530 | 0.000 |
Shares | 95.310 | 95.310 | 0.000 |
Other | 0.170 | 0.170 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 22.234 | 19.304 |
Price to Book | 7.182 | 3.239 |
Price to Sales | 5.006 | 2.299 |
Price to Cash Flow | 17.297 | 12.706 |
Dividend Yield | 1.244 | 2.010 |
5 Years Earnings Growth | 9.104 | 9.875 |
Name | Net % | Category Average |
---|---|---|
Technology | 43.010 | 20.723 |
Healthcare | 38.880 | 12.291 |
Communication Services | 18.100 | 9.477 |
Number of long holdings: 33
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Apple | US0378331005 | 8.75 | 231.59 | -0.51% | |
Microsoft | US5949181045 | 7.86 | 520.17 | -0.44% | |
NVIDIA | US67066G1040 | 7.73 | 180.45 | -0.86% | |
Alphabet A | US02079K3059 | 7.23 | 203.90 | +0.47% | |
Eli Lilly | US5324571083 | 5.90 | 701.23 | +2.45% | |
Meta Platforms | US30303M1027 | 5.43 | 785.23 | +0.40% | |
Roche Holding Participation | CH0012032048 | 5.30 | 256.00 | +2.36% | |
Novartis | CH0012005267 | 4.89 | 99.49 | +0.93% | |
Thermo Fisher Scientific | US8835561023 | 3.62 | 489.01 | +0.82% | |
Medtronic | IE00BTN1Y115 | 3.55 | 93.02 | +1.13% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Renaissance Global Growth | 5.07B | 0.71 | 11.39 | 8.63 | ||
Renaissance Global Growth Class F | 5.07B | 1.47 | 12.84 | 10.04 | ||
Renaissance International Equity | 1.76B | -0.61 | 6.29 | 5.10 | ||
Renaissance International Equity Cl | 1.76B | 0.13 | 7.66 | 6.50 | ||
Renaissance US Equity Income Fund | 1.53B | 1.09 | 8.08 | 7.78 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review